For Drug Toxicity Testing, microRNAs Hold Promise But More Work Remains | GenomeWeb

While much attention has been focused on the use of microRNAs for diagnostic applications, a number of pharmaceutical firms have been exploring the non-coding RNAs' potential as biomarkers of drug-related toxicity.

However, these efforts are early stage and require additional work before miRNAs could reliably replace traditional biomarkers, according to data presented this week at the Cambridge Healthtech Institute microRNA as Biomarkers and Diagnostics meeting in Boston.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.